Genprex, Inc. (GNPX)
Automate Your Wheel Strategy on GNPX
With Tiblio's Option Bot, you can configure your own wheel strategy including GNPX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GNPX
- Rev/Share 0.0006
- Book/Share 0.2534
- PB 1.2148
- Debt/Equity 0.0
- CurrentRatio 1.944
- ROIC -3.924
- MktCap 8563335.0
- FreeCF/Share -1.0467
- PFCF -0.5359
- PE -0.2459
- Debt/Assets 0.0
- DivYield 0
- ROE -6.6467
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Genprex to Participate at BIO 2025 International Convention
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
AUSTIN, Texas , June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2025 International Convention taking place June 16-19, 2025 in Boston, Mass. In attendance from Genprex's executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing.
Read More
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas , May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive patent license agreement with UTHealth Houston granting Genprex exclusivity and commercial rights relating to its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for the potential treatment of glioblastoma. The subject patent is co-owned by Genprex and UTHealth Houston, and the license provides Genprex with patent exclusivity.
Read More
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas , April 30, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC). This data were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 …
Read More
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
Published: April 29, 2025 by: PRNewsWire
Sentiment: Neutral
Novel Gene Therapy Program Offers a Promising Opportunity for Curative Therapy in Diabetes AUSTIN, Texas , April 29, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming American Society of Gene and Cell Therapy's (ASGCT) 28th Annual Meeting being held May 13-17, 2025 in New Orleans, Louisiana. The collaborators will present positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate.
Read More
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
Additional Gene Therapy Technology Expands Genprex's Portfolio of Oncology Licenses AUSTIN, Texas , April 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has signed an exclusive patent license agreement with NYU Langone Health related to the drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid). The therapy is under investigation as a potential treatment for mesothelioma.
Read More
About Genprex, Inc. (GNPX)
- IPO Date 2018-03-29
- Website https://www.genprex.com
- Industry Biotechnology
- CEO Mr. Ryan M. Confer M.S.
- Employees 15